PMID- 37439826
OWN - NLM
STAT- MEDLINE
DCOM- 20230831
LR  - 20230831
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 149
IP  - 13
DP  - 2023 Oct
TI  - Influence of background cardiovascular risk factors on VEGF inhibitor-related 
      adverse vascular events in patients with non-small cell lung cancer: a 
      retrospective study.
PG  - 12435-12442
LID - 10.1007/s00432-023-05092-4 [doi]
AB  - PURPOSE: Vascular endothelial growth factor (VEGF) inhibitors are widely used in 
      chemotherapy for non-small lung cancer (NSCLC). The purpose of the current study 
      was to examine the impact of background cardiovascular risk factors on VEGF 
      inhibitor-related adverse vascular events (VEGF-related AVEs) in patients with 
      NSCLC who also had comorbidities. METHODS: We conducted a retrospective study of 
      118 NSCLC patients treated with bevacizumab or ramucirumab from April 2010 to 
      December 2022. We compared baseline cardiovascular risk factors with VEGF-related 
      AVEs. RESULTS: VEGF-related AVEs and discontinuation due to VEGF-related AVEs 
      were reported in 54 patients and 21 patients, respectively. VEGF-related AVEs 
      were significantly more common with male sex, smoking history, history of 
      hypertension, dyslipidemia, diabetes mellitus, or cardiovascular disease. 
      Discontinuation due to VEGF-related AVEs was significantly more common in 
      patients with history of hypertension or chronic kidney disease. VEGF-related 
      AVEs were significantly more common in patients with >/= 3 cardiovascular risk 
      factors than patients with < 3. Discontinuation due to VEGF-related AVEs was 
      significantly more common in patients with >/= 4 cardiovascular risk factors than 
      patients with < 4. Multivariate analysis demonstrated that male sex, 
      hypertension, and >/= 6 cycles of VEGF inhibitors were each associated with 
      VEGF-related AVEs and hypertension was associated with discontinuation due to 
      VEGF-related AVEs. CONCLUSION: Our study demonstrated that history of 
      hypertension was independently associated with increased risk of both 
      VEGF-related AVEs and discontinuation due to VEGF-related AVEs. In conclusion, we 
      need to be aware of VEGF-related AVEs when using VEGF inhibitors for patients 
      with >/= 3 cardiovascular risk factors.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Naito, Tomoyuki
AU  - Naito T
AD  - Department of Respiratory Medicine, Mitsui Memorial Hospital, Kanda-Izumicho 1, 
      Chiyoda-ku, Tokyo, 101-8643, Japan.
AD  - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, 
      Nippon Medical School, Tokyo, Japan.
FAU - Minegishi, Yuji
AU  - Minegishi Y
AD  - Department of Respiratory Medicine, Mitsui Memorial Hospital, Kanda-Izumicho 1, 
      Chiyoda-ku, Tokyo, 101-8643, Japan. yminegis@nms.ac.jp.
AD  - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, 
      Nippon Medical School, Tokyo, Japan. yminegis@nms.ac.jp.
FAU - Shiraishi, Hideaki
AU  - Shiraishi H
AD  - Department of Respiratory Medicine, Mitsui Memorial Hospital, Kanda-Izumicho 1, 
      Chiyoda-ku, Tokyo, 101-8643, Japan.
FAU - Hoshino, Tatsuhiko
AU  - Hoshino T
AD  - Surgical Department of Respiratory Center, Mitsui Memorial Hospital, 1 
      Kandaizumi-cho, Chiyoda-ku, Tokyo, 101-8643, Japan.
FAU - Maeda, Junichi
AU  - Maeda J
AD  - Surgical Department of Respiratory Center, Mitsui Memorial Hospital, 1 
      Kandaizumi-cho, Chiyoda-ku, Tokyo, 101-8643, Japan.
FAU - Yokota, Toshiya
AU  - Yokota T
AD  - Surgical Department of Respiratory Center, Mitsui Memorial Hospital, 1 
      Kandaizumi-cho, Chiyoda-ku, Tokyo, 101-8643, Japan.
FAU - Ikeda, Shingo
AU  - Ikeda S
AD  - Surgical Department of Respiratory Center, Mitsui Memorial Hospital, 1 
      Kandaizumi-cho, Chiyoda-ku, Tokyo, 101-8643, Japan.
FAU - Akihiko, Miyanaga
AU  - Akihiko M
AD  - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, 
      Nippon Medical School, Tokyo, Japan.
FAU - Seike, Masahiro
AU  - Seike M
AD  - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, 
      Nippon Medical School, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230713
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Angiogenesis Inhibitors)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Humans
MH  - Male
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Vascular Endothelial Growth Factor A
MH  - *Lung Neoplasms/drug therapy/chemically induced
MH  - *Cardiovascular Diseases/chemically induced/epidemiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Angiogenesis Inhibitors/adverse effects
MH  - Bevacizumab/adverse effects
MH  - Heart Disease Risk Factors
MH  - *Hypertension/chemically induced/epidemiology/drug therapy
OTO - NOTNLM
OT  - Bevacizumab
OT  - Cardiovascular event
OT  - Cardiovascular risk factor
OT  - Non-small cell lung cancer
OT  - Ramucirumab
OT  - Vascular endothelial growth factor inhibitor
EDAT- 2023/07/13 12:31
MHDA- 2023/08/31 06:42
CRDT- 2023/07/13 11:06
PHST- 2023/06/28 00:00 [received]
PHST- 2023/06/30 00:00 [accepted]
PHST- 2023/08/31 06:42 [medline]
PHST- 2023/07/13 12:31 [pubmed]
PHST- 2023/07/13 11:06 [entrez]
AID - 10.1007/s00432-023-05092-4 [pii]
AID - 10.1007/s00432-023-05092-4 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2023 Oct;149(13):12435-12442. doi: 
      10.1007/s00432-023-05092-4. Epub 2023 Jul 13.